One of the most important investment projects scheduled for completion in Belarus this year is the launch of pharmaceutical production in Beshenkovichi. The project is invested by Lithuanian, Belarusian, Indian and Russian businesspeople.
According to Chairman of the Board of the Lithuanian company Avia Solutions Group Gediminas Žiemelis, the construction of the pharmaceutical plant Nativita in Beshenkovichi will have been completed by the end of this year. The project has been financed since 2014.
According to him, Belarus has 12 patented medicines, which will be produced at the factory. Total product line will be of 32 products. During the organization of production Indian technology is being used, Lithuanians act as a source of funds.
The project with a 15 million dollar investment was launched at the end of 2014. The factory is mastering the manufacture of medications for treatment of cancer, autoimmune and severe infectious diseases.
Avia Solutions Group is one of the four most significant members of the investment project in the pharmaceutical industry of Belarus in recent years, specializing in aircraft maintenance and management of the airports in the Baltic States and the CIS. Investments in pharmaceutics are a non-core activity of Avia Solutions Group.
The Belarusian side in the project is represented by the major distributor of medications VitVar.
Technology for the new production with a share in this business is provided by the Indian company Natco Pharma, drug development is carried out by the Russian company Biocad.
Biocad is one of the most promising Russian pharmaceutical companies. A few dozen agents of their own development are produced at its three plants in Russia. The company invests a lot in innovation. In 2014, half of the company’s shares were acquired by the investment fund Millhouse Capital and 20 per cent of the shares were taken up by the company Pharmstandard.
Under the materials of ej.by